Eleven Brand/Generic Drug Patent Settlements Reported To FTC Since January
This article was originally published in The Pink Sheet Daily
Executive Summary
None of those settlements involved “reverse payments,” FTC staff attorney Kades says. In total, 17 agreements have been reported to FTC since January.
You may also be interested in...
Waxman/Hatch Changes Make “Reverse Payments” Less Likely, FTC Says
The Waxman/Hatch reforms included in the 2003 Medicare Modernization Act make "reverse payment" settlements of patent litigation less likely, the Federal Trade Commission says in a Supreme Court filing.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.